"Immune dysregulation represents a dynamic process evolving during time, often towards hypogammaglobulineamia, especially therapy-related or during disease progression,8-11 and thus with a different subdivision over time. Nevertheless our study constitutes a ‘photograph’ at diagnosis of CLL patients and prognosis has been evaluated in this specific setting.
Prior studies reported an occurrence of hypogammaglobulinaemia in CLL patients ranging from 25% to 70%, but data still remain limited because of the heterogeneity of the examined cohorts, the small series and the inclusion of both treated and untreated patients.12-14
Here, we present data from our study of 1505 patients with newly diagnosed CLL regarding the occurrence of hypogammaglobulinaemia, IgG and IgM gammopathy and their significance in terms of survival and clinical and biological features of the disease"
Results
We retrospectively analyzed 1505 consecutive CLL patients from four different Italian centres diagnosed in the time span from 1987 to 2016. All patients had, at diagnosis, a baseline assessment including their serum Ig profile and immunofixation if a peak was detected at SPEP. Median age was 66 years old (range 26–96 years old), with a slight male predominance (52%, P = 0·589) and the median follow-up was 78 months (range 1–332 months) (Table I).
A total of 73 patients (4·8%) had IgM monoclonal gammopathy (IgM/CLL) detected by immunofixation with a restriction of the κ light chain in 70% and of the λ light chain in 30% of the cases. IgG monoclonal gammopathy (IgG/CLL) was found in 149 patients (10%) with an identical light chain restriction as in IgM/CLL (70% κ and 30% λ). In 88% of the IgG/CLL and 80% of the IgM/CLL cases the light chain isotype of the monoclonal paraprotein and the surface immunoglobulin of the CLL cells were the same (P < 0·0001). The remaining 1283 patients lacked paraprotein at SPEP or immunofixation. Among these, 1083 patients (72%) had normal Ig levels while 200 patients (13·2%) showed hypogammaglobulinaemia.
Clinical and biological characteristics of patients belonging to each of the four subgroups are shown in Table II.
Hypogammaglobulinaemia, the most frequent Ig aberration present at diagnosis in CLL (13·2%). After baseline assessment, in hypogamma/CLL group 42·4% of patients had reduced IgA, 52·7% had reduced IgM and 31·7% were deficient of all Ig classes. In this subset of patients, we evaluated if there was a specific threshold for Ig level under which patients had an inferior outcome and we detected it for IgA level.
CONCLUSION:
"Furthermore, beyond the well-known independent prognostic markers (e.g. IGHV status mutation, Binet/RAI stage, del17p), the presence of qualitative and quantitative Ig alterations does not have any impact on OS."
The post here: